

**Supplementary table 2.** Comparison of baseline characteristics between the complete cohort of the CANONIC study (n=1349) and the cohort of the current ancillary study (n=779).

| Variable                        | All CANONIC patients<br>(n=1349) | Ancillary study<br>(n=779) | p-value |
|---------------------------------|----------------------------------|----------------------------|---------|
| <b>Age (years)</b>              | 57 ± 12                          | 58 ± 12                    | 0.335   |
| <b>Gender (male), n (%)</b>     | 854 (63.3)                       | 512 (65.7)                 | 0.262   |
| <b>Background, n (%)</b>        |                                  |                            |         |
| Diabetes                        | 302 (22.8)                       | 190 (24.9)                 | 0.259   |
| Coronary heart disease          | 71 (5.5)                         | 37 (5.1)                   | 0.657   |
| <b>Etiology, n (%)</b>          |                                  |                            |         |
| Alcohol                         | 820 (61.3)                       | 471 (61.0)                 | 0.901   |
| Hepatitis B                     | 77 (6.0)                         | 42 (5.7)                   | 0.824   |
| Hepatitis C                     | 374 (28.9)                       | 235 (31.9)                 | 0.162   |
| NAFLD                           | 73 (5.7)                         | 33 (4.5)                   | 0.253   |
| Cholestatic                     | 35 (2.7)                         | 17 (2.3)                   | 0.573   |
| Cryptogenic                     | 75 (5.8)                         | 43 (5.8)                   | 0.998   |
| Other                           | 105 (8.2)                        | 53 (7.2)                   | 0.444   |
| <b>Physical exam</b>            |                                  |                            |         |
| SBP (mmHg)                      | 116 ± 19                         | 116 ± 18                   | 0.997   |
| DBP (mmHg)                      | 67 ± 12                          | 67 ± 11                    | 0.893   |
| MAP (mmHg)                      | 83 ± 12                          | 83 ± 12                    | 0.947   |
| <b>Clinical features, n (%)</b> |                                  |                            |         |
| Ascites                         | 1209 (89.6)                      | 691 (88.7)                 | 0.509   |
| Bacterial infection             | 325 (24.2)                       | 177 (22.8)                 | 0.490   |
| SIRS                            | 305 (7.3)                        | 153 (69.9)                 | 0.332   |
| Sepsis                          | 73 (5.5)                         | 37 (4.8)                   | 0.504   |
| HE                              | 460 (34.1)                       | 240 (30.8)                 | 0.117   |
| <b>Laboratory data</b>          |                                  |                            |         |
| WBC (x 10 <sup>9</sup> /L)      | 6.2 (4.3-9.2)                    | 5.9 (4.1-9.3)              | 0.313   |
| CRP (mg/L)                      | 18 (7-43)                        | 18 (7-41)                  | 0.330   |
| Bilirubin (mg/dL)               | 3.0 (1.6-7.4)                    | 2.9 (1.5-6.5)              | 0.196   |
| Prothrombine time (s)           | 18 (15-24)                       | 18 (16-25)                 | 0.303   |
| INR                             | 1.5 (1.3-1.9)                    | 1.5 (1.3-1.8)              | 0.119   |
| Creatinine (mg/dL)              | 0.9 (0.7-1.4)                    | 0.9 (0.7-1.4)              | 0.695   |
| Sodium (mmol/L)                 | 135 ± 6                          | 135 ± 6                    | 0.421   |
| <b>Scores</b>                   |                                  |                            |         |
| Child-Pugh                      | 9.7 ± 2.1                        | 9.4 ± 2.1                  | 0.003   |
| MELD                            | 19 ± 7                           | 18 ± 7                     | 0.024   |
| CLIF-C OF                       | 7.8 ± 2.1                        | 7.5 ± 1.7                  | 0.002   |
| <b>Treatments, n (%)</b>        |                                  |                            |         |
| ICU admission                   | 198 (14.8)                       | 102 (13.2)                 | 0.314   |
| Antibiotics                     | 255 (19.7)                       | 142 (18.8)                 | 0.633   |
| Transfusion <sup>§</sup>        | 152 (11.7)                       | 87 (11.5)                  | 0.872   |
| Variceal bleeding <sup>*</sup>  | 143 (11.0)                       | 87 (11.5)                  | 0.733   |
| Vasoactive agents <sup>#</sup>  | 83 (6.4)                         | 39 (5.1)                   | 0.250   |
| Mechanical ventilation          | 42 (3.1)                         | 14 (1.8)                   | 0.068   |
| Renal replacement therapy       | 21 (1.6)                         | 3 (0.4)                    | 0.014   |
| Beta-blockers use               | 133 (10.3)                       | 66 (8.7)                   | 0.259   |

ACLF, acute-on-chronic liver failure; NAFLD: non-alcoholic fatty liver disease; PBC: primary biliary cholangitis; SBP, systolic blood pressure, DBP, diastolic blood pressure; MAP, mean arterial blood pressure; SIRS, systemic inflammatory response syndrome; HE: hepatic encephalopathy; WBC: white blood cell count; CRP: C-reactive protein; INR: international normalized ratio; MELD: Model for End-stage Liver Disease; MELD-Na: Model for End-Stage Liver Disease with incorporation of serum sodium concentration; CLIF-C OF: CLIF-Consortium Organ Failure Score

Variables are expressed as mean ± SD, median (IQR) or numbers and percentage.

<sup>a</sup> p-value of comparisons between patients with and without ACLF

\* at any time during follow-up

<sup>§</sup> includes transfusion of red cells package, fresh-frozen plasma, platelets, and cryoprecipitates.

<sup>#</sup> includes any vasoactive drug used for circulatory support, variceal bleeding or hepatorenal syndrome.